MeiraGTx Secures Up to $400M From Oberland to Fund Gene Therapies
MeiraGTx entered a largely non-dilutive financing of up to $400 million with Oberland Capital to support its late-stage retinitis pigmentosa and xerostomia gene therapy programs.
Funding a gene therapy through to commercial launch is brutally expensive, which is why MeiraGTx's latest financing matters. On July 7, 2026, the company announced a strategic investment of up to $400 million from Oberland Capital Management to advance its late-stage eye and salivary-gland programs.
MeiraGTx develops adeno-associated virus gene therapies, with lead assets botaretigene sparoparvovec (bota-vec) for X-linked retinitis pigmentosa and AAV2-hAQP1 for radiation-induced xerostomia.
The upside case is the largely non-dilutive nature of the deal. Of the total, up to $375 million comes as capped royalty financing and up to $25 million as equity. An initial $135 million tranche includes $125 million tied to low single-digit royalties and a $10 million equity investment, with additional $50 million tranches unlocking on data and regulatory milestones through 2028. That structure lets MeiraGTx push toward potential commercialization without repeatedly tapping a volatile equity market.
Royalty financing still burdens future product sales, and those sales depend on clinical and regulatory outcomes that remain unproven. This is market commentary, not investment advice — small-cap biotech stocks are highly speculative and you can lose your entire investment.
Get the next one first.
Small-cap biotech catalysts, filings and movers — free.